1. Home
  2. LMAT vs MESO Comparison

LMAT vs MESO Comparison

Compare LMAT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$83.30

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$18.61

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
MESO
Founded
1983
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
LMAT
MESO
Price
$83.30
$18.61
Analyst Decision
Buy
Strong Buy
Analyst Count
6
2
Target Price
$101.83
$24.00
AVG Volume (30 Days)
177.1K
224.5K
Earning Date
11-06-2025
02-25-2026
Dividend Yield
0.98%
N/A
EPS Growth
27.40
N/A
EPS
2.32
N/A
Revenue
$240,866,000.00
$17,198,000.00
Revenue This Year
$15.17
$576.59
Revenue Next Year
$9.07
$41.15
P/E Ratio
$35.31
N/A
Revenue Growth
13.07
191.39
52 Week Low
$71.42
$9.61
52 Week High
$105.55
$21.00

Technical Indicators

Market Signals
Indicator
LMAT
MESO
Relative Strength Index (RSI) 48.54 55.06
Support Level $79.40 $17.90
Resistance Level $86.00 $18.73
Average True Range (ATR) 2.22 0.52
MACD -0.06 -0.16
Stochastic Oscillator 45.64 35.48

Price Performance

Historical Comparison
LMAT
MESO

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: